Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation

Sai Ravi Kiran Pingali, Michelle Mathiason, Steven Lovrich, Ronald Go

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We report the emergence of chronic myelogenous leukemia (CML) in a patient with JAK2V617F-positive polycythemia vera after 15 years of phlebotomy. The polycythemia vera clinical and molecular findings were suppressed at the time of CML diagnosis, only to re-emerge after the leukemia was successfully treated with imatinib. We explored the potential association between myeloproliferative disorders and CML in the context of the current literature and found a higher-than-expected coincidence based on known epidemiologic data for each specific condition. We hypothesize that myeloproliferative disorder (JAK2V617F or molecular events that cause JAK2V617F) is a risk factor for CML (BCR-ABL translocation). Because of therapeutic implications, clinicians should be aware that the conditions co-occur more frequently than once thought.

Original languageEnglish (US)
JournalClinical Lymphoma and Myeloma
Volume9
Issue number5
DOIs
StatePublished - Oct 1 2009
Externally publishedYes

Fingerprint

Myeloproliferative Disorders
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polycythemia Vera
Phlebotomy
Leukemia
Therapeutics

Keywords

  • Erythrocytosis
  • Myelofibrosis
  • Phlebotomy
  • Polycythemia vera
  • Sleep apnea

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder : JAK2V617F as a potential risk factor for BCR-ABL translocation. / Pingali, Sai Ravi Kiran; Mathiason, Michelle; Lovrich, Steven; Go, Ronald.

In: Clinical Lymphoma and Myeloma, Vol. 9, No. 5, 01.10.2009.

Research output: Contribution to journalArticle

@article{5b17069517db41478e2352949bcef521,
title = "Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation",
abstract = "We report the emergence of chronic myelogenous leukemia (CML) in a patient with JAK2V617F-positive polycythemia vera after 15 years of phlebotomy. The polycythemia vera clinical and molecular findings were suppressed at the time of CML diagnosis, only to re-emerge after the leukemia was successfully treated with imatinib. We explored the potential association between myeloproliferative disorders and CML in the context of the current literature and found a higher-than-expected coincidence based on known epidemiologic data for each specific condition. We hypothesize that myeloproliferative disorder (JAK2V617F or molecular events that cause JAK2V617F) is a risk factor for CML (BCR-ABL translocation). Because of therapeutic implications, clinicians should be aware that the conditions co-occur more frequently than once thought.",
keywords = "Erythrocytosis, Myelofibrosis, Phlebotomy, Polycythemia vera, Sleep apnea",
author = "Pingali, {Sai Ravi Kiran} and Michelle Mathiason and Steven Lovrich and Ronald Go",
year = "2009",
month = "10",
day = "1",
doi = "10.3816/CLM.2009.n.080",
language = "English (US)",
volume = "9",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "5",

}

TY - JOUR

T1 - Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder

T2 - JAK2V617F as a potential risk factor for BCR-ABL translocation

AU - Pingali, Sai Ravi Kiran

AU - Mathiason, Michelle

AU - Lovrich, Steven

AU - Go, Ronald

PY - 2009/10/1

Y1 - 2009/10/1

N2 - We report the emergence of chronic myelogenous leukemia (CML) in a patient with JAK2V617F-positive polycythemia vera after 15 years of phlebotomy. The polycythemia vera clinical and molecular findings were suppressed at the time of CML diagnosis, only to re-emerge after the leukemia was successfully treated with imatinib. We explored the potential association between myeloproliferative disorders and CML in the context of the current literature and found a higher-than-expected coincidence based on known epidemiologic data for each specific condition. We hypothesize that myeloproliferative disorder (JAK2V617F or molecular events that cause JAK2V617F) is a risk factor for CML (BCR-ABL translocation). Because of therapeutic implications, clinicians should be aware that the conditions co-occur more frequently than once thought.

AB - We report the emergence of chronic myelogenous leukemia (CML) in a patient with JAK2V617F-positive polycythemia vera after 15 years of phlebotomy. The polycythemia vera clinical and molecular findings were suppressed at the time of CML diagnosis, only to re-emerge after the leukemia was successfully treated with imatinib. We explored the potential association between myeloproliferative disorders and CML in the context of the current literature and found a higher-than-expected coincidence based on known epidemiologic data for each specific condition. We hypothesize that myeloproliferative disorder (JAK2V617F or molecular events that cause JAK2V617F) is a risk factor for CML (BCR-ABL translocation). Because of therapeutic implications, clinicians should be aware that the conditions co-occur more frequently than once thought.

KW - Erythrocytosis

KW - Myelofibrosis

KW - Phlebotomy

KW - Polycythemia vera

KW - Sleep apnea

UR - http://www.scopus.com/inward/record.url?scp=70350633820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350633820&partnerID=8YFLogxK

U2 - 10.3816/CLM.2009.n.080

DO - 10.3816/CLM.2009.n.080

M3 - Article

C2 - 19858050

AN - SCOPUS:70350633820

VL - 9

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 5

ER -